Re-orienting the immune system: Durable tumor regression and successful re-induction therapy using anti-PD1 antibodies

Oncoimmunology. 2013 Apr 1;2(4):e23661. doi: 10.4161/onci.23661.


The blockade of immune regulatory checkpoints is emerging as a powerful anticancer strategy. We recently reported long-term results from the first-in-human clinical trial of anti-PD1 antibody-based immunotherapy, demonstrating durable tumor control off-therapy in subjects affected by colorectal and kidney cancer, as well as successful re-induction therapy in a melanoma patient.

Keywords: anti-PD1; cancer immunotherapy; immune checkpoint blockade; nivolumab; re-induction.